About Paraneoplastic antigen Ma1
Paraneoplastic antigen Ma1 (PNMA1) is a protein
from Homo sapiens identified by UniProt accession
Q8ND90, 353 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | Paraneoplastic antigen Ma1 |
|---|
| UniProt accession | Q8ND90 |
|---|
| Gene | PNMA1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 353 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (52)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.07
- neoplasm · score 0.07
- FEV/FVC ratio · score 0.07
- reticulocyte count · score 0.05
- mean corpuscular hemoglobin concentration · score 0.04
- reticulocyte measurement · score 0.04
- systolic blood pressure · score 0.04
- testosterone measurement · score 0.04
- sex hormone-binding globulin measurement · score 0.03
- hemoglobin measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8ND90-F1 | alphafold | PREDICTED | 80.70 | — |
Amino-acid sequence (353 residues)
MAMTLLEDWC RGMDVNSQRA LLVWGIPVNC DEAEIEETLQ AAMPQVSYRM LGRMFWREEN AKAALLELTG AVDYAAIPRE MPGKGGVWKV LFKPPTSDAE FLERLHLFLA REGWTVQDVA RVLGFQNPTP TPGPEMPAEM LNYILDNVIQ PLVESIWYKR LTLFSGRDIP GPGEETFDPW LEHTNEVLEE WQVSDVEKRR RLMESLRGPA ADVIRILKSN NPAITTAECL KALEQVFGSV ESSRDAQIKF LNTYQNPGEK LSAYVIRLEP LLQKVVEKGA IDKDNVNQAR LEQVIAGANH SGAIRRQLWL TGAGEGPAPN LFQLLVQIRE EEAKEEEEEA EATLLQLGLE GHF
Explore Paraneoplastic antigen Ma1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets